기본 정보
- 표준 SMILES
CC1=C(C)C(=O)C(C(CCCCCC(=O)O)c2ccccc2)=C(C)C1=O- InChIKey
ZBVKEHDGYSLCCC-UHFFFAOYSA-N- 분자식
- C22H26O4
- 평균 분자량
- 354.4 g/mol
- 단동위원소 질량
- 354.18310931
개요
Seratrodast is an organic molecular entity.
이름 및 식별자
- 우선 이름
- Seratrodast
- IUPAC
- 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
- 영어명
- Seratrodast
- 분자식
- C22H26O4
- 분자량
- 354.44
이름 및 동의어
이름 더 보기
데이터베이스 식별자
- CAS
112665-43-7- PubChem CID
- 2449
- DTXSID
DTXSID4021397- ChEMBL
CHEMBL70972- ChEBI
CHEBI:32126- UNII
- 4U58JM421N
- EC Number
- 692-169-8
- Nikkaji
- J1.633.058B
물성
구조 계산 물성
- XLogP
- 4.4
- 극성 표면적
- 71.4 Ų
- 수소 결합 공여자 수
- 1
- 수소 결합 수용자 수
- 4
- 회전 가능 결합 수
- 8
- 무거운 원자 수
- 26
- 형식 전하
- 0
- 복잡도
- 633
물리화학적 성질
- 녹는점
- 118 · 118-120°C
- 끓는 점
- 522.3 · 522.3±49.0 °C(Predicted)
- 밀도
- 1.14 · 1.140±0.06 g/cm3(Predicted)
- 저장 조건
- -20 °C · Sealed in dry,Store in freezer, under -20°C
- 용해도
- 클로로포름(약간 용해됨), 메탄올(약간 용해됨)
- 산도 계수 (pKa)
- 4.76 · 4.76±0.10(Predicted)
- 물리적 상태
- 노란색-주황색 고체.
- 색상
- 옅은 주황색에서 노란색까지
- Merck
- 14 · 14,8459
- InChI
- InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)
- InChIKey
- ZBVKEHDGYSLCCC-UHFFFAOYSA-N
- SMILES
- C1(C)C(=O)C(C)=C(C(C2=CC=CC=C2)CCCCCC(=O)O)C(=O)C=1C
화학적 성질
Pale Orange Solid
안전 및 규제
GHS 분류
GHS Classification
Warning
H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory.
유해성 정보
안전 데이터
- wgk
- WGK 3
- rtecs
- DA1600050
- HS 번호
- 2918.30.3000
- Hazard Classifications
- Repr. 2
- 스토리지 클래스
- 11 - Combustible Solids
화학 및 산업
약리 정보
ATC Code
R - Respiratory system
QR - Respiratory system
MeSH Pharmacological Classification
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Compounds that inhibit the action of prostaglandins.
Drugs that are used to treat asthma.
응용 분야
개요Seratrodast, a novel benzoquinone derivative, is the first thromboxane A2 (TxA2) receptor antagonist to reach the market. It is orally active for the treatment of bronchospastic disorders such as asthma. TxA2, a metabolite of the arachidonate cascade, is involved in several cardiovascular and respiratory diseases through its potent biological effects on platelet aggregation and constriction of vascular and respiratory smooth muscles. Seratrodast potently inhibits platelet aggregation and bronchoconstriction induced by a TxA2 mimic and by a variety of spasmogenic prostanoids including PGF2α, PGD2 and 9α,11β-PGF2. Seratrodast shows excellent efficacy in asthma and has been reported to be potentially useful in hyper-responsive disorder. The R-(+)- seratrodast was reported to be the active isomer.
상·하류 제품 정보
상류 원료
공급사50 곳
관련 반응
연결된 노트
불러오는 중…